AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00923598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% and 0.4% perineural ropivicaine
Description: Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
Study NCT00797030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine and sodium carboximethycellulose
Description: Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
Study NCT04000971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive or Primary Stroke Center
Description: Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
Study NCT03657342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT03657342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
Study NCT03972202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
Study NCT03972202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
Study NCT03972202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
Study NCT03972202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-motor behavioral testing
Description: Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
Study NCT03972202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-motor behavioral testing
Description: Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
Study NCT03656848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QFR
Description: QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
Study NCT03656848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
Study NCT03656848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
Study NCT00700544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy treatment (see arm) + norethandrolone
Description: oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years
Study NCT00700544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy treatment (see arms)
Description: Induction chemotherapy + maintenance chemotherapy
Study NCT03103698 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: To demonstrate the monitoring of perioperative analgesia
Description: To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
Study NCT03103698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard preoperative evaluation of analgesia
Description: To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
Study NCT02740062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIBS system for evaluation and non invasive current stimulation
Study NCT02740062 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIBS system for evaluation and non invasive current stimulation
Study NCT04142424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
Study NCT00797030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sodium carboximethycellulose
Description: Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
Study NCT03976544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
Study NCT03976544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
Study NCT04663737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silmitasertib
Description: Capsules
Study NCT04663737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
Study NCT02013791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol
Study NCT02013791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol
Study NCT02262117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Description: No specific medical care
Study NCT02262117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: specific treatment
Description: Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
Study NCT03811002 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT03811002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT03811002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03811002 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03811002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03811002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03811002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03811002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03811002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04204083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc
Description: A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
Study NCT00060541 — intervention group
Intervention type: PROCEDURE
Intervention: Laboratory tests
Study NCT00060541 — intervention group
Intervention type: PROCEDURE
Intervention: Radiological exams
Study NCT00775853 — intervention group
Intervention type: DRUG
Intervention: 6-[18F]Fluorodopamine
Study NCT00775853 — intervention group
Intervention type: DRUG
Intervention: 6-[18F]Fluorodopa
Study NCT00775853 — intervention group
Intervention type: DRUG
Intervention: 13N-Ammonia
Study NCT00582478 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participants will be followed regularly at 3, 6, 12, and 18-month intervals
Study NCT02772731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy plus additional Shave Margin
Description: For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin.
Study NCT02772731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial mastectomy
Description: Surgeons will be instructed to close after partial mastectomy with no further excision.
Study NCT04167553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15136
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Study NCT04167553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Study NCT04142424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Study NCT03492424 — intervention group
Intervention type: DEVICE
Intervention: cryotherapy
Description: Subjects will receive focal cryotherapy for treatment of prostate cancer
Study NCT03533517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventricular Restoration
Description: AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
Study NCT02919631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Anaplerotic dietary oil
Study NCT02919631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Safflower oil
Study NCT03924869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT
Study NCT03924869 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT
Study NCT03924869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03924869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT03213678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study NCT03213678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03213678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET
Study NCT03213678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03213678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samotolisib
Description: Given PO
Study NCT03213678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT00587886 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
Study NCT00587886 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers.
Study NCT03717142 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LUM Imaging System
Description: Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
Study NCT04668560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five ways to wellbeing course
Description: A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
Study NCT04002947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-EPOCH
Description: Vincristine 1.4 mg/m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2/day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
Study NCT04002947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for 6 cycles.
Study NCT04002947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
Study NCT04002947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for the first 10 days for 6 cycles.
Study NCT01292226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g PO BID for 24 weeks
Study NCT01292226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibody induction
Description: According to manufacturer recommendation
Study NCT01292226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: According to manufacturer recommendation
Study NCT01292226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: According to manufacturer recommendation
Study NCT03190213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
Study NCT00001465 — intervention group
Intervention type: DEVICE
Intervention: Toshibia Aquilion One CT
Description: The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
Study NCT04746794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Population-level screening
Description: The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.
Study NCT01028287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
Study NCT04468984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral
Study NCT04468984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study NCT04468984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Tablet/Capsule; Oral or Solution for Subcutaneous Injection
Study NCT03698071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03698071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 6 ml
Study NCT05531474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.